Coherus rises on FDA approval for drug-delivery device

Coherus Oncology

26/12/2023 21:49

** Shares of Coherus BioSciences  CHRS.O  rise 25.23% to
$2.73 after the bell
    ** Co says U.S. FDA has approved its drug delivery device
for Udenyca
    ** Udenyca, a biosimilar to Amgen's  AMGN.O 
infection-fighting treatment Neulasta, is administered the day
after chemotherapy to decrease the incidence of infection
     ** Commercial availability of the device is planned for the
first quarter of 2024 - CHRS
    ** Stock down ~72% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))